{
    "organizations": [],
    "uuid": "3b48c54f8f7cc518a87388c6881f19e624b80121",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aeglea-biotherapeutics-q4-revenue/brief-aeglea-biotherapeutics-q4-revenue-1-5-mln-vs-1-2-mln-idUSASC09RYL",
    "ord_in_thread": 0,
    "title": "BRIEF-Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 31 AM / in 7 minutes BRIEF-Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln Reuters Staff 1 Min Read March 13 (Reuters) - Aeglea Bio Therapeutics Inc: * AEGLEA BIOTHERAPEUTICS PROVIDES KEY CLINICAL DATA UPDATE FROM PHASE 1/2 TRIAL IN ARGINASE 1 DEFICIENCY AND REPORTS Q4 AND FULL YEAR 2017 FINANCIAL RESULTS * Q4 REVENUE VIEW $1.2 MILLION — THOMSON REUTERS I/B/E/S * ‍REPEAT DOSES OF COMPANY’S PEGZILARGINASE PRODUCES MARKED AND SUSTAINED REDUCTIONS IN PLASMA ARGININE LEVELS​ * ‍ACCOMPANYING REDUCTIONS IN OTHER RELATED GUANIDINO COMPOUNDS ALSO SEEN IN STUDY​ * ‍EXPECTS TO REPORT PEDIATRIC AND ADULT REPEAT DOSE DATA IN PATIENTS WITH ARGINASE 1 DEFICIENCY IN Q3 2018​ * AEGLEA BIO - ‍AS OF DEC 31, 2017, HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION​ * AEGLEA BIO THERAPEUTICS - BASED ON CURRENT OPERATING PLAN, BELIEVES HAS SUFFICIENT CAPITAL RESOURCES TO FUND ANTICIPATED OPERATIONS THROUGH Q3 2019 * NET LOSS TOTALED $6.5 MILLION AND $5.5 MILLION FOR Q4 OF 2017 AND 2016, RESPECTIVELY Source text for Eikon: Further company coverage:",
    "published": "2018-03-13T13:29:00.000+02:00",
    "crawled": "2018-03-13T13:52:27.084+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "minute",
        "biotherapeutics",
        "q4",
        "revenue",
        "mln",
        "v",
        "mln",
        "reuters",
        "staff",
        "min",
        "read",
        "march",
        "reuters",
        "aeglea",
        "bio",
        "therapeutic",
        "inc",
        "aeglea",
        "biotherapeutics",
        "provides",
        "key",
        "clinical",
        "data",
        "update",
        "phase",
        "trial",
        "arginase",
        "deficiency",
        "report",
        "q4",
        "full",
        "year",
        "financial",
        "result",
        "q4",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "dos",
        "company",
        "pegzilarginase",
        "produce",
        "marked",
        "sustained",
        "reduction",
        "plasma",
        "arginine",
        "reduction",
        "related",
        "guanidino",
        "compound",
        "also",
        "seen",
        "report",
        "pediatric",
        "adult",
        "repeat",
        "dose",
        "data",
        "patient",
        "arginase",
        "deficiency",
        "q3",
        "aeglea",
        "bio",
        "dec",
        "available",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "aeglea",
        "bio",
        "therapeutic",
        "based",
        "current",
        "operating",
        "plan",
        "belief",
        "sufficient",
        "capital",
        "resource",
        "fund",
        "anticipated",
        "operation",
        "q3",
        "net",
        "loss",
        "totaled",
        "million",
        "million",
        "q4",
        "respectively",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}